{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T04:53:11Z","timestamp":1774327991259,"version":"3.50.1"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatocellular carcinoma (HCC) is a significant cause of death worldwide. HCC is a highly vascular tumor, and proangiogenic cytokines such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor may play crucial roles in this disease. Sorafenib, a multikinase inhibitor that blocks VEGF and PDGF signaling, was the first systemic therapy to demonstrate improved survival in patients with advanced HCC. Several other drugs targeting VEGF are in development. Because of the anticipation of eventual resistance to anti-VEGF therapies, drugs that also target alternative proangiogenic pathways are being investigated. Recent clinical and preclinical data along with ongoing studies are reviewed.<\/jats:p>","DOI":"10.1634\/theoncologist.2012-0388","type":"journal-article","created":{"date-parts":[[2013,4,11]],"date-time":"2013-04-11T04:15:13Z","timestamp":1365653713000},"page":"430-438","source":"Crossref","is-referenced-by-count":47,"title":["Antiangiogenic Therapies for Advanced Hepatocellular Carcinoma"],"prefix":"10.1093","volume":"18","author":[{"given":"Keeran R.","family":"Sampat","sequence":"first","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bert","family":"O'Neil","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,4,10]]},"reference":[{"key":"2021122308321949800_B1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"2021122308321949800_B2","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","article-title":"Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis","volume":"132","author":"El-Serag","year":"2007","journal-title":"Gastroenterology"},{"key":"2021122308321949800_B3","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"Llovet","year":"2003","journal-title":"Lancet"},{"key":"2021122308321949800_B4","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/SLA.0b013e3181a38eb5","article-title":"Predictors of survival after resection of early hepatocellular carcinoma","volume":"249","author":"Nathan","year":"2009","journal-title":"Ann Surg"},{"key":"2021122308321949800_B5","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1200\/JCO.2010.28.7805","article-title":"Hepatocellular carcinoma: Consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308321949800_B6","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jhep.2008.12.011","article-title":"Angiogenesis in liver disease","volume":"50","author":"Fern\u00e1ndez","year":"2009","journal-title":"J Hepatol"},{"key":"2021122308321949800_B7","first-page":"379","article-title":"Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: A comparison with angiopoietin\/Tie pathway","volume":"22","author":"Dhar","year":"2002","journal-title":"Anticancer Res"},{"key":"2021122308321949800_B8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/jso.21109","article-title":"Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients","volume":"98","author":"Tseng","year":"2008","journal-title":"J Surg Oncol"},{"key":"2021122308321949800_B9","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.5858\/2000-124-1061-IEOVEG","article-title":"Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis","volume":"124","author":"Park","year":"2000","journal-title":"Arch Pathol Lab Med"},{"key":"2021122308321949800_B10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0008-6363(00)00281-9","article-title":"Molecular mechanisms of blood vessel growth","volume":"49","author":"Conway","year":"2001","journal-title":"Cardiovasc Res"},{"key":"2021122308321949800_B11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1471-4914(02)02394-8","article-title":"The role of fibroblast growth factors in vascular development","volume":"8","author":"Javerzat","year":"2002","journal-title":"Trends Mol Med"},{"key":"2021122308321949800_B12","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1053\/jhep.2002.32541","article-title":"Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma","volume":"35","author":"Yoshiji","year":"2002","journal-title":"Hepatology"},{"key":"2021122308321949800_B13","volume-title":"Nexavar [package insert]","year":"2011"},{"key":"2021122308321949800_B14","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1111\/j.1582-4934.2009.00692.x","article-title":"Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma","volume":"13","author":"Huynh","year":"2009","journal-title":"J Cell Mol Med"},{"key":"2021122308321949800_B15","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122308321949800_B16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"issue":"suppl 15","key":"2021122308321949800_B17","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1200\/jco.2011.29.15_suppl.4001","article-title":"Global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib (GIDEON) second interim analysis in more than 1,500 patients: Clinical findings in patients with liver dysfunction","volume":"29","author":"Marrero","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308321949800_B18","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2010.1672","article-title":"Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial","volume":"304","author":"Abou-Alfa","year":"2010","journal-title":"JAMA"},{"key":"2021122308321949800_B19","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1111\/j.1349-7006.2008.00909.x","article-title":"Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients","volume":"99","author":"Shim","year":"2008","journal-title":"Cancer Sci"},{"key":"2021122308321949800_B20","first-page":"LBA154","article-title":"Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial","volume":"30","author":"Lencioni","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"key":"2021122308321949800_B21","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2021122308321949800_B22","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm.2537","article-title":"Tumor angiogenesis: Molecular pathways and therapeutic targets","volume":"17","author":"Weis","year":"2011","journal-title":"Nat Med"},{"issue":"suppl 15","key":"2021122308321949800_B23","article-title":"Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC)","volume":"29","author":"Cheng","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308321949800_B24","volume-title":"Avastin [package insert]","year":"2009"},{"key":"2021122308321949800_B25","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1200\/JCO.2007.15.9947","article-title":"Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma","volume":"26","author":"Siegel","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308321949800_B26","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1002\/cncr.25889","article-title":"Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma","volume":"117","author":"Sun","year":"2011","journal-title":"Cancer"},{"key":"2021122308321949800_B27","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/sj.bjc.6605580","article-title":"Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma","volume":"102","author":"Hsu","year":"2010","journal-title":"Br J Cancer"},{"key":"2021122308321949800_B28","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2005.04.9130","article-title":"Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma","volume":"24","author":"Zhu","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308321949800_B29","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1046\/j.1365-2036.2000.00778.x","article-title":"Primary prophylaxis for portal hypertensive bleeding in cirrhosis","volume":"14","author":"Vlachogiannakos","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"2021122308321949800_B30","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2008.18.3301","article-title":"Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma","volume":"27","author":"Thomas","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308321949800_B31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/376062a0","article-title":"Failure of blood-island formation and vasculogenesis in flk-1-deficient mice","volume":"376","author":"Shalaby","year":"1995","journal-title":"Nature"},{"key":"2021122308321949800_B32","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1248\/bpb.34.1785","article-title":"Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy","volume":"34","author":"Takahashi","year":"2011","journal-title":"Biol Pharm Bull"},{"key":"2021122308321949800_B33","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","article-title":"Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2","volume":"28","author":"Spratlin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2021122308321949800_B34","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1200\/jco.2010.28.15_suppl.4083","article-title":"A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC)","volume":"28","author":"Zhu","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308321949800_B35","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1200\/JCO.2008.21.7125","article-title":"Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies","volume":"27","author":"Wong","year":"2009","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2021122308321949800_B36","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1200\/jco.2010.28.15_suppl.4038","article-title":"Linifanib phase II trial in patients with advanced hepatocellular carcinoma (HCC)","volume":"28","author":"Toh","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308321949800_B37","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/COC.0b013e3182118cdf","article-title":"Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: A phase II north central cancer treatment group clinical trial","volume":"35","author":"Alberts","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"2021122308321949800_B38","doi-asserted-by":"crossref","first-page":"6146","DOI":"10.1158\/1078-0432.CCR-08-0509","article-title":"Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma","volume":"14","author":"Huynh","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122308321949800_B39","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/1535-7163.MCT-09-0472","article-title":"The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases","volume":"9","author":"Bhide","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"2021122308321949800_B40","volume-title":"FGF signaling dysregulation in HCC and role in the development of acquired resistance to anti-angiogenic therapies","author":"Tovar","year":"2011"},{"key":"2021122308321949800_B41","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1158\/1078-0432.CCR-10-2011","article-title":"Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma","volume":"17","author":"Park","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2021122308321949800_B42","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1158\/1078-0432.CCR-11-1991","article-title":"Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma","volume":"18","author":"Finn","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"suppl 2","key":"2021122308321949800_B43","doi-asserted-by":"crossref","first-page":"S549","DOI":"10.1016\/S0168-8278(12)61409-3","article-title":"Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: results from the phase 3 BRISK-PS study","volume":"56","author":"Llovet","year":"2012","journal-title":"J Hepatol"},{"key":"2021122308321949800_B44","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"2021122308321949800_B45","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"2021122308321949800_B46","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1002\/cncr.26165","article-title":"Phase 1\/2 study of everolimus in advanced hepatocellular carcinoma","volume":"117","author":"Zhu","year":"2011","journal-title":"Cancer"},{"key":"2021122308321949800_B47","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00280-010-1320-2","article-title":"A phase I\/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma","volume":"67","author":"Kanai","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122308321949800_B48","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"2021122308321949800_B49","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S1470-2045(09)70240-2","article-title":"Resistance to targeted therapy in renal-cell carcinoma","volume":"10","author":"Rini","year":"2009","journal-title":"Lancet Oncol"},{"key":"2021122308321949800_B50","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.1158\/1078-0432.CCR-11-0659","article-title":"Beyond VEGF: Inhibition of the fibroblast growth factor pathway and antiangiogenesis","volume":"17","author":"Lieu","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2021122308321949800_B51","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","article-title":"Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors","volume":"8","author":"Casanovas","year":"2005","journal-title":"Cancer Cell"},{"key":"2021122308321949800_B52","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2009.24.8252","article-title":"Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance","volume":"28","author":"Kopetz","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308321949800_B53","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/hep.24099","article-title":"Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis","volume":"53","author":"Gauglhofer","year":"2011","journal-title":"Hepatology"},{"key":"2021122308321949800_B54","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1172\/JCI42405","article-title":"Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma","volume":"121","author":"Cascone","year":"2011","journal-title":"J Clin Invest"},{"key":"2021122308321949800_B55","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1158\/1535-7163.MCT-09-0274","article-title":"Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition","volume":"8","author":"Rapisarda","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"2021122308321949800_B56","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1002\/cncr.23092","article-title":"Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer","volume":"110","author":"Yuan","year":"2007","journal-title":"Cancer"},{"key":"2021122308321949800_B57","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrd3455","article-title":"Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases","volume":"10","author":"Carmeliet","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"2021122308321949800_B58","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nrc2894","article-title":"Targeting the ANGPT-TIE2 pathway in malignancy","volume":"10","author":"Huang","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"2021122308321949800_B59","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1478-3231.2011.02541.x","article-title":"Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib","volume":"31","author":"Lee","year":"2011","journal-title":"Liver Int"},{"key":"2021122308321949800_B60","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jhep.2012.08.022","article-title":"Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma","volume":"58","author":"Jiang","year":"2012","journal-title":"J Hepatol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/pdf\/10.1634\/theoncologist.2012-0388","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/full-xml\/10.1634\/theoncologist.2012-0388","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/4\/430\/41856115\/oncolo_18_4_430.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/4\/430\/41856115\/oncolo_18_4_430.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T19:05:39Z","timestamp":1715195139000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/18\/4\/430\/6398726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,1]]},"references-count":60,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,4,10]]},"published-print":{"date-parts":[[2013,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2012-0388","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,4,1]]},"published":{"date-parts":[[2013,4,1]]}}}